{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:07:41Z","timestamp":1790712461772,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jaad.2023.02.040","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T12:05:34Z","timestamp":1677758734000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study"],"prefix":"10.1016","volume":"89","author":[{"given":"Boni E.","family":"Elewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan J.","family":"Anadkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mrowietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Quaresma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bachelez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2023.02.040_bib1","doi-asserted-by":"crossref","first-page":"e043666","DOI":"10.1136\/bmjopen-2020-043666","article-title":"Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare","volume":"11","author":"Choon","year":"2021","journal-title":"BMJ Open"},{"issue":"26","key":"10.1016\/j.jaad.2023.02.040_bib2","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.02.040_bib3","series-title":"Spesolimab prescribing information","year":"2022"},{"key":"10.1016\/j.jaad.2023.02.040_bib4","series-title":"European Commission approves SPEVIGO\u00ae (spesolimab) for generalized pustular psoriasis flares","year":"2022"},{"key":"10.1016\/j.jaad.2023.02.040_bib5","series-title":"First-ever treatment aimed at alleviating acute symptoms in pustular psoriasis [media release]","year":"2022"},{"key":"10.1016\/j.jaad.2023.02.040_bib6","series-title":"The spesolimab injection approved for marketing","year":"2022"},{"key":"10.1016\/j.jaad.2023.02.040_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.18999","article-title":"Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI)","author":"Burden","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2023.02.040_bib8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2023.02.040_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40257-021-00655-y","article-title":"Pathophysiology of generalized pustular psoriasis","volume":"23","author":"Marrakchi","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2023.02.040_bib10","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/1346-8138.14523","article-title":"Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP","volume":"45","author":"Fujita","year":"2018","journal-title":"J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2023.02.040_bib11","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/1346-8138.13306","article-title":"Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study","volume":"43","author":"Imafuku","year":"2016","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.02.040_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjd.14702","article-title":"Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study","volume":"176","author":"Yamasaki","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.02.040_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2023.02.040_bib14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/14740338.2020.1785427","article-title":"Biologics in the treatment of pustular psoriasis","volume":"19","author":"Wang","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2023.02.040_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","article-title":"Treatment options and goals for patients with generalized pustular psoriasis","volume":"23","author":"Krueger","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.02.040_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/1346-8138.14294","article-title":"Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study","volume":"45","author":"Sano","year":"2018","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.040_bib17","doi-asserted-by":"crossref","first-page":"e14660","DOI":"10.1111\/dth.14660","article-title":"New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection","volume":"34","author":"Ceccarelli","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2023.02.040_bib18","doi-asserted-by":"crossref","unstructured":"Burden AD, Bachelez H, Choon SE, et\u00a0al. Validation of the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) scale for assessing severity of GPP. American Academy of Dermatology; 2022.","DOI":"10.1016\/j.jaad.2022.06.904"},{"issue":"4","key":"10.1016\/j.jaad.2023.02.040_bib19","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2021.09.035","article-title":"Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis","volume":"149","author":"Baum","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300350X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300350X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:23:32Z","timestamp":1759274612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222300350X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S019096222300350X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.040","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}